Nicholas J. Vogelzang, MD

Nicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.

The idea was to stimulate the immune system with a vaccine containing 3 pieces of the prostate cancer. When patients relapse after 1 to 3 years with prostate cancer, the prostate-specific antigen (PSA) often increases, Vogelzang explains. Researchers hypothesized that if you could stimulate the immune system with the virus by a bystander effect, it would work.

Videos

Rationale for Phase III PROSPECT Trial in Prostate Cancer

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.

MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, the study results showed.

MPDL3280A was well tolerated during the study.

More research needs to be done in order to determine which patients will benefit the most from this treatment.

MPDL3280A in Patients with Metastatic Bladder Cancer

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.

Vogelzang says he and his colleagues believe that radium-223 can be combined safely with all hormonal and immune therapies. In one study, radium-223 was given with chemotherapy and researchers found that less chemotherapy had to be administered. Currently, Vogelzang notes, the FDA recommends that radium-223 should not be given with chemotherapy.

The oncology community believes that radium-223 can be combined safely with all hormonal and immune therapies

When given with radium-223, chemotherapy has to be given in a smaller amount

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.

Nicholas J. Vogelzang, MD | Authors

Articles

Rationale for Phase III PROSPECT Trial in Prostate Cancer

MPDL3280A in Patients with Metastatic Bladder Cancer

Treatment With Radium-223 and Chemotherapy for Prostate Cancer